Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
The adoption of camrelizumab plus rivoceranib as a treatment option is not only associated with improved health outcomes but also represents a cost-effective choice in China.
Authors
- Huide Zhu
- Zhiwei Zheng (ORCID: https://orcid.org/0000-0002-7815-3221)
- Hongfu Cai (ORCID: https://orcid.org/0000-0002-4923-4882)
- Jingwen Lin
Institutions
- Fujian Medical University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Union Hospital (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/bmjopen-2023-079603
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.11